Alkem launches Pertuza in India to treat HER2-positive breast cancer
Alkem Laboratories has announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Alkem
Industry growth weakens sharply in Mar’24
For the 12 months through Mar’24, IPM grew 7.6 per cent YoY and prices/volume/new launches increased by 4.0 per cent/0.7 per…
Biosergen, Alkem collaborate to develop anti-infective for severe fungal infections
Once the clinical trials are successfully completed in India, Biosergen and Alkem aim to expand its use for similar patient groups…
Enzene Biosciences launches Cetuximab, biosimilar of cancer drug Erbitux
Cetuximab is a therapeutic chimeric monoclonal antibody that is used as a targeted therapy for metastatic colorectal cancer (mCRC)…
US FDA completes inspection of Alkem’s manufacturing facility in Indore
In response to Form 483 issued by the US FDA containing one observation, the company had submitted a detailed CAPA plan to the…
Alkem becomes first Indian company to launch novel antibiotic for MDR infections
This is in line with company’s endeavour to ensure affordability, accessibility and availability while saving the lives of…
Alkem launches breast cancer treatment drug palbociclib (Palbo) in India
The drug comes in capsule form in multiple dose strengths with varied pricing ranges, including 125 mg at Rs 6,125/- for 21…
Redefining job roles to build competitive compliance
Express Pharma, in association with SAP India, as part of the Life Sciences Industry Knowledge Exchange Forum, recently hosted a…
Alkem launches anti-epileptic drug BRIVASURE (Brivaracetam)
Brivaracetam has shown promise in patients with epilepsy whose seizures persist despite adequate treatment.
Alkem launches favipiravir under brand name Alfluenza
Favipiravir is approved by the DCGI restricted emergency use in India for the treatment of mild to moderate cases of COVID-19